Cargando…

Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?

BACKGROUND AND OBJECTIVE: Prostate cancer (PCa) has seen improved detection methods with a subsequent rise in disease prevalence, making novel prostate cancer treatment options an exciting yet controversial topic. Current treatment modalities encompass traditional approaches, namely surgery (radical...

Descripción completa

Detalles Bibliográficos
Autores principales: Williams, Thomas R., Benjamin, Tavya G. R., Schwartz, Michael J., Rastinehad, Ardeshir R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906217/
https://www.ncbi.nlm.nih.gov/pubmed/36760247
http://dx.doi.org/10.21037/atm-22-2337
_version_ 1784883958907928576
author Williams, Thomas R.
Benjamin, Tavya G. R.
Schwartz, Michael J.
Rastinehad, Ardeshir R.
author_facet Williams, Thomas R.
Benjamin, Tavya G. R.
Schwartz, Michael J.
Rastinehad, Ardeshir R.
author_sort Williams, Thomas R.
collection PubMed
description BACKGROUND AND OBJECTIVE: Prostate cancer (PCa) has seen improved detection methods with a subsequent rise in disease prevalence, making novel prostate cancer treatment options an exciting yet controversial topic. Current treatment modalities encompass traditional approaches, namely surgery (radical prostatectomy) and radiation therapy. While heralded as a standard of care, these modalities may come with significant risk profiles, primarily sexual (erectile dysfunction) and urinary incontinence. Advances in technology and imaging, specifically multi-parametric MRI, have afforded great leaps in targeted focal therapy as a primary treatment option for localized PCa. This review identifies and highlights published data for novel and emerging PCa focal therapy (FT) modalities. METHODS: Our study identified and reviewed the current literature for relevant investigations related to primary FT modalities as they apply to the treatment of prostate cancer. After an internal review, relevant studies (published in English, between 2000–April 2022) were included for analysis and summarization. KEY CONTENT AND FINDINGS: We provide a concise review of several novel focal therapy modalities that offer realistic potential for primary treatment of localized prostate cancer. Our narrative includes studies that primarily include their respective results, specifically focusing on those that reported both oncologic and quality-of-life outcomes after focal therapy. While still in its cumulative infancy, we discuss the current limitations, future directions, and advancements that hopefully push focal therapy into the limelight. CONCLUSIONS: While many of the mentioned focal therapies for PCa have shown promising pathologic and quality of life outcomes, further clinical evidence is required to change overall management guidelines and recommendations. The advantages of FT in avoiding sexual and urinary side-effects of radical surgery or radiation are apparent; however, it is necessary to recognize the need for further long-term evidence that is durable over time and comparable to current gold-standard treatment options.
format Online
Article
Text
id pubmed-9906217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-99062172023-02-08 Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm? Williams, Thomas R. Benjamin, Tavya G. R. Schwartz, Michael J. Rastinehad, Ardeshir R. Ann Transl Med Review Article BACKGROUND AND OBJECTIVE: Prostate cancer (PCa) has seen improved detection methods with a subsequent rise in disease prevalence, making novel prostate cancer treatment options an exciting yet controversial topic. Current treatment modalities encompass traditional approaches, namely surgery (radical prostatectomy) and radiation therapy. While heralded as a standard of care, these modalities may come with significant risk profiles, primarily sexual (erectile dysfunction) and urinary incontinence. Advances in technology and imaging, specifically multi-parametric MRI, have afforded great leaps in targeted focal therapy as a primary treatment option for localized PCa. This review identifies and highlights published data for novel and emerging PCa focal therapy (FT) modalities. METHODS: Our study identified and reviewed the current literature for relevant investigations related to primary FT modalities as they apply to the treatment of prostate cancer. After an internal review, relevant studies (published in English, between 2000–April 2022) were included for analysis and summarization. KEY CONTENT AND FINDINGS: We provide a concise review of several novel focal therapy modalities that offer realistic potential for primary treatment of localized prostate cancer. Our narrative includes studies that primarily include their respective results, specifically focusing on those that reported both oncologic and quality-of-life outcomes after focal therapy. While still in its cumulative infancy, we discuss the current limitations, future directions, and advancements that hopefully push focal therapy into the limelight. CONCLUSIONS: While many of the mentioned focal therapies for PCa have shown promising pathologic and quality of life outcomes, further clinical evidence is required to change overall management guidelines and recommendations. The advantages of FT in avoiding sexual and urinary side-effects of radical surgery or radiation are apparent; however, it is necessary to recognize the need for further long-term evidence that is durable over time and comparable to current gold-standard treatment options. AME Publishing Company 2022-11-30 2023-01-15 /pmc/articles/PMC9906217/ /pubmed/36760247 http://dx.doi.org/10.21037/atm-22-2337 Text en 2023 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Review Article
Williams, Thomas R.
Benjamin, Tavya G. R.
Schwartz, Michael J.
Rastinehad, Ardeshir R.
Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title_full Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title_fullStr Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title_full_unstemmed Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title_short Narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
title_sort narrative review—focal therapy: are we ready to change the prostate cancer treatment paradigm?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906217/
https://www.ncbi.nlm.nih.gov/pubmed/36760247
http://dx.doi.org/10.21037/atm-22-2337
work_keys_str_mv AT williamsthomasr narrativereviewfocaltherapyarewereadytochangetheprostatecancertreatmentparadigm
AT benjamintavyagr narrativereviewfocaltherapyarewereadytochangetheprostatecancertreatmentparadigm
AT schwartzmichaelj narrativereviewfocaltherapyarewereadytochangetheprostatecancertreatmentparadigm
AT rastinehadardeshirr narrativereviewfocaltherapyarewereadytochangetheprostatecancertreatmentparadigm